Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Dec 31;12(12):3233-3240.
doi: 10.21037/tcr-23-1515. Epub 2023 Nov 13.

The growing role of PARP inhibitors in the treatment of metastatic castration-resistant prostate cancer

John Panzone  1 , Gavrielle J Rood  1 , Hanan Goldberg  1
Affiliations
Editorial

The growing role of PARP inhibitors in the treatment of metastatic castration-resistant prostate cancer

John Panzone et al. Transl Cancer Res. .
No abstract available

Keywords: Prostate cancer; castration-resistant; germline mutations; poly (ADP-ribose) polymerase inhibitors (PARPis).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1515/coif). H.G. reports personal payment as a Pfizer speaker and Bayer speaker, and personal payment for Myovant and Bayer advisory board. The other authors have no conflicts of interest to declare.

Comment on

  • Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
    Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nolè F, Staffurth J, Redfern C, Sáez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH; TRITON3 Investigators. Fizazi K, et al. N Engl J Med. 2023 Feb 23;388(8):719-732. doi: 10.1056/NEJMoa2214676. Epub 2023 Feb 16. N Engl J Med. 2023. PMID: 36795891 Free PMC article. Clinical Trial.

References

    1. Desai K, McManus JM, Sharifi N. Hormonal Therapy for Prostate Cancer. Endocr Rev 2021;42:354-73. 10.1210/endrev/bnab002 - DOI - PMC - PubMed
    1. Ryan CJ, Ke X, Lafeuille MH, et al. Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States. J Urol 2021;206:1420-9. 10.1097/JU.0000000000002121 - DOI - PMC - PubMed
    1. Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med 2016;375:443-53. 10.1056/NEJMoa1603144 - DOI - PMC - PubMed
    1. Wu MS, Goldberg H. Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations. Cancer Manag Res 2022;14:3159-74. 10.2147/CMAR.S353411 - DOI - PMC - PubMed
    1. de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 2020;382:2091-102. 10.1056/NEJMoa1911440 - DOI - PubMed